Insurer Aetna Sets Coverage Rates for Genomic Health's Oncotype DX | GenomeWeb
NEW YORK (GenomeWeb News) — Genomic Health today said that Aetna has set payment rates for its Oncotype DX test for early-stage breast cancer patients.
Genomic Health said Aetna, which  began covering the test in August, has set rates for all of its plans for breast cancer patients for the test, which quantifies the odds of breast cancer recurrence and predicts the chances of the effectiveness of chemotherapy treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.